Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

PASSING OF CONSISTENCY EVALUATION FOR

"LENALIDOMIDE CAPSULES"

The board of directors (the "Board") of Sino Biopharmaceutical Limited (the "Company", together with its subsidiaries, the "Group") announces that the oncology medicine "Lenalidomide Capsules" (brand name "Anxian"( 安顯)) of Chia-Tai Tianqing Pharmaceutical Group Co., Ltd, a subsidiary of the Company, has obtained the approval for Consistency of Quality and Efficacy Evaluation for Generic Drugs ("Consistency Evaluation") granted by the National Medical Products Administration of the People's Republic of China.

Lenalidomide is indicated for the treatment of patients with multiple myeloma who have received at least one other form of treatment. The Lenalidomide Capsules developed by the Group have achieved outstanding sales performance and rapid growth since they were approved for launch in January 2019. The passing of the Consistency Evaluation is a further recognition of the quality and efficacy of the product.

By order of the Board

Sino Biopharmaceutical Limited

Tse, Theresa Y Y

Chairwoman

Hong Kong, 31 October 2019

As at the date of this announcement, the Board comprises eight Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and four Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.

Attachments

  • Original document
  • Permalink

Disclaimer

Sino Biopharmaceutical Limited published this content on 31 October 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 October 2019 08:41:02 UTC